Gravity Analytica

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

BLTE 11.05.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Webcast on financial results and business update

Full Press Release SEC Filings Our BLTE Tweets

About Gravity Analytica

Recent Filings

PDF Version

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) --Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2024.

Webcast InformationDate:Tuesday, November 12, 2024Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link:https://wsw.com/webcast/cc/blte5/1423080

Webcast Link InstructionsYou can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website athttps://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.

About Belite BioBelite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us onTwitter,Instagram,LinkedIn,Facebookor visit us atwww.belitebio.com.

Media and Investor Relations Contact:Jennifer Wuir@belitebio.com

Julie Fallonbelite@argotpartners.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com